Shared Molecular Targets Confer Resistance over Short and Long Evolutionary Timescales.
Ontology highlight
ABSTRACT: Pre-existing and de novo genetic variants can both drive adaptation to environmental changes, but their relative contributions and interplay remain poorly understood. Here we investigated the evolutionary dynamics in drug-treated yeast populations with different levels of pre-existing variation by experimental evolution coupled with time-resolved sequencing and phenotyping. We found a doubling of pre-existing variation alone boosts the adaptation by 64.1% and 51.5% in hydroxyurea and rapamycin, respectively. The causative pre-existing and de novo variants were selected on shared targets: RNR4 in hydroxyurea and TOR1, TOR2 in rapamycin. Interestingly, the pre-existing and de novo TOR variants map to different functional domains and act via distinct mechanisms. The pre-existing TOR variants
SUBMITTER: Li J
PROVIDER: S-EPMC6445301 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA